Skip to content
ChickenStockChickenStock
ResearchVCYT
Veracyte logo

Veracyte (VCYT) stock

NASDAQ

$24.33-1.22%(-0.30)

As of the Nov 13, 2026 close (U.S. Eastern)

Events and reference metrics · 1

Compares the share price with the company's earnings, net assets and sales. Check trading status and financial notes separately.

Price date for the multiples · Nov 13, 2026 · Financial period · Trailing twelve months

P/E and P/S use the latest four quarters where available · P/B uses the latest equity · Computed in-house by ChickenStock

P/E

15.46x

P/B

1.37x

P/S

3.37x

Latest earnings

SEC filings

Jul–Sep 2026(FY2026 Q3)

Revenue increased 15.2% from the same period a year earlier.

Key reported figures come first. Select one to see the same quarter across three years.

See the same quarter across three years →

Filed Nov 5, 2026 · 10-Q · SEC EDGAR

Reported results are from SEC EDGAR filings. Reference information only, not investment advice.

Insider transactions

Recent Form 4 filings grouped by person, date and transaction type.

23 SEC filings
  • Wygant JonathanVP, Chief Accounting Officer · Oct 28, 2026Shares withheld for taxes1,306 shares · $66K
    Avg. price $50.3141,920 shares held after
  • EASTHAM KARINDirector · Oct 27, 2026Open-market sale14,850 shares · $743K
    Avg. price $50.004910,247 shares held after
  • Holstein JensDirector · Oct 27, 2026Open-market sale7,500 shares · $375K
    Avg. price $5027,471 shares held after
  • EASTHAM KARINDirector · Oct 27, 2026Option exercise10,000 shares · $270K
    Avg. price $27.0125,097 shares held after
  • Holstein JensDirector · Oct 27, 2026Option exercise7,500 shares · $265K
    Avg. price $35.334,971 shares held after
  • Bhanji MunaDirector · Oct 19, 2026Open-market sale1,864 shares · $81K
    Avg. price $43.740,854 shares held after
  • Holstein JensDirector · Sep 24, 2026Open-market sale7,500 shares · $353K
    Avg. price $4727,471 shares held after
  • Holstein JensDirector · Sep 24, 2026Option exercise7,500 shares · $265K
    Avg. price $35.334,971 shares held after
  • Leite JohnGlobal Chief Commercial Off · Sep 21, 2026Open-market sale4,015 shares · $161K
    Avg. price $40124,329 shares held after
  • Holstein JensDirector · Sep 14, 2026Open-market sale5,000 shares · $205K
    Avg. price $40.949427,471 shares held after
  • Febbo Phillip G.Chief Scientific & Med Officer · Sep 4, 2026Open-market sale13,110 shares · $564K
    Avg. price $43.0519
    Show 2 price lots
    • 10,405 shares × $42.8933$446K
    • 2,705 shares × $43.6618$118K
  • Chambers RebeccaChief Financial Officer · Sep 4, 2026Open-market sale3,652 shares · $157K
    Avg. price $43.0981
    Show 2 price lots
    • 2,477 shares × $42.8059$106K
    • 1,175 shares × $43.714$51K
  • McGuire AnnieEVP, General Counsel · Sep 4, 2026Open-market sale3,254 shares · $140K
    Avg. price $43.0891
    Show 2 price lots
    • 2,154 shares × $42.7916$92K
    • 1,100 shares × $43.6718$48K
  • Stapley MarcChief Executive Officer · Sep 2, 2026Shares withheld for taxes8,782 shares · $394K
    Avg. price $44.88432,073 shares held after
  • Leite JohnGlobal Chief Commercial Off · Sep 2, 2026Shares withheld for taxes3,961 shares · $178K
    Avg. price $44.88128,344 shares held after
  • Febbo Phillip G.Chief Scientific & Med Officer · Sep 2, 2026Shares withheld for taxes3,639 shares · $163K
    Avg. price $44.88146,158 shares held after
  • Chambers RebeccaChief Financial Officer · Sep 2, 2026Shares withheld for taxes3,603 shares · $162K
    Avg. price $44.88169,677 shares held after
  • McGuire AnnieEVP, General Counsel · Sep 2, 2026Shares withheld for taxes3,215 shares · $144K
    Avg. price $44.88134,414 shares held after
  • Wygant JonathanVP, Chief Accounting Officer · Sep 2, 2026Shares withheld for taxes1,361 shares · $61K
    Avg. price $44.8843,226 shares held after
  • Bhanji MunaDirector · Sep 1, 2026Open-market sale1,864 shares · $80K
    Avg. price $42.9742,718 shares held after

Only transactions reported on SEC Form 4 are shown. A sale may follow a pre-arranged 10b5-1 plan, and items such as option exercises or shares withheld for taxes are not open-market trades.

Recent SEC filings

40 filings

Filings submitted to the U.S. Securities and Exchange Commission (EDGAR). Dates are SEC filing dates (U.S. Eastern). Form and item names are the official SEC titles. The Earnings and Risk tags come directly from form types and item codes; they are not written by AI. Insider ownership reports (Forms 3, 4 and 5) are excluded.

Company overview

Expand ▾

Veracyte (VCYT) stock information

NASDAQ

Veracyte (VCYT) is listed on NASDAQ. Its market capitalization is about $2B. On trailing-twelve-month earnings the P/E ratio is 15.46, and the P/B ratio is 1.37. Return on equity is 8.9%. These figures are computed in-house from official filings and are reference information only.

Veracyte — frequently asked questions

What is the P/E ratio of Veracyte (VCYT)?
On a trailing-twelve-month basis, VCYT trades at a P/E ratio of 15.46. It is calculated as market capitalization divided by net income attributable to controlling interests, using official filings. Reference information only.
What is the market capitalization of Veracyte?
VCYT has a market capitalization of about $2B. The figure moves with the share price and is refreshed each trading day.
Is this page investment advice?
No. Every figure on this page is factual reference information compiled from public filings. It is not investment advice, not a price forecast and not a recommendation to buy or sell. Investment decisions rest with the user.

All metrics, scores, and content provided by ChickenStock are reference information derived from market data. They are not investment advice or a solicitation to trade. Investment decisions and their consequences rest with the user.